In preclinical studies, REGN5458 increased surface levels of BCMA on MM cell lines, in addition to inducing T cell killing of MM cells and cytotoxicity in primary human plasma cells (117). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.